Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

25,720 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 7,363
Recruiting: 3,965
Ph III recruiting: 535
Growth YoY: +10.3%
Industry share: 25%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3,404)

clinicaltrialsPublishedShowing 3,701–3,750 of 3,853 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06109402	Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer	not yet recruiting	Phase 2	160	Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER	1	Dec 19, 2023	clinicaltrials
NCT06173986	Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer	recruiting	Phase 1 / Phase 2	50	Shanghai Chest HospitalOTHER	1	Dec 18, 2023